Deal-Making Firm On Fosun’s Agenda As Overseas Revenues Spurt
Executive Summary
With overseas revenues rising sharply in the first half of 2017, Fosun Pharma expects to build on its global investment strategy at a fast pace, striking more deals to acquire products and companies from developed markets.
You may also be interested in...
China Investment Roundup: Spotlight On Oncology
Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.
Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
Fosun Tweaks Gland Deal Amid Limbo In India
China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.